Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Gains from Investment Securities (2019 - 2025)

Korro Bio (KRRO) has disclosed Gains from Investment Securities for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1.2 million, compared with a TTM value of $4.0 million through Sep 2025, up 286.08%, and an annual FY2024 reading of $141000.0, up 422.22% over the prior year.
  • Gains from Investment Securities was $1.2 million for Q3 2025 at Korro Bio, down from $2.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.0 million in Q1 2021 and bottomed at -$2.2 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $1.6 million, with a median of $828000.0 recorded in 2024.
  • Peak annual rise in Gains from Investment Securities hit 397.76% in 2024, while the deepest fall reached 2955.58% in 2024.
  • Year by year, Gains from Investment Securities stood at $701873.0 in 2021, then soared by 227.41% to $2.3 million in 2022, then plummeted by 196.48% to -$2.2 million in 2023, then soared by 104.24% to $94000.0 in 2024, then surged by 1158.51% to $1.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for KRRO at $1.2 million in Q3 2025, $2.3 million in Q2 2025, and $501000.0 in Q1 2025.